menu
    • menu
    [{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"NDI-034858","moa":"TYK2 tyrosine kinase (TYK2)","graph1":"Immunology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":6,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":6,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"NDI-034858","moa":"TYK2 tyrosine kinase (TYK2)","graph1":"Immunology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":6,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":6,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NDI-034858","moa":"TYK2 tyrosine kinase (TYK2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NDI-034858","moa":"TYK2 tyrosine kinase (TYK2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NDI-034858","moa":"TYK2 tyrosine kinase (TYK2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NDI-034858","moa":"TYK2 tyrosine kinase (TYK2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"NDI-101150","moa":"HPK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nimbus Therapeutics","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.20999999999999999,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Google Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Nimbus Therapeutics \/ Google Ventures"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NDI-101150","moa":"||HPK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NDI-101150","moa":"HPK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NDI-219216","moa":"WRN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Nimbus Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Nimbus Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NMBS-1","moa":"HPK1","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Nimbus Therapeutics","amount2":0.5,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0.5,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Nimbus Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Schrodinger","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Schrodinger","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Schrodinger"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Anagenex","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Nimbus Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Nimbus Therapeutics \/ Nimbus Therapeutics"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NTX-801","moa":"Casitas B-lineage lymphoma B","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NMBS-2","moa":"HPK1","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0.5,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.5,"dosageForm":"Undisclosed","sponsorNew":"Nimbus Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Eli Lilly"}]

    Find Clinical Drug Pipeline Developments & Deals by Nimbus Therapeutics

    Menu

    Nimbus Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NDI-219216

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nimbus Starts First Human Trial of WRN Inhibitor NDI-219216 for MSI-H Tumors

                            Details : NDI-219216 is a highly potent and selective non-covalent investigational inhibitor of Werner syndrome helicase (WRN) activity being developed for the treatment of neoplasms.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 25, 2025

                            Lead Product(s) : NDI-219216

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Sponsor : Eli Lilly

                            Deal Size : $496.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nimbus Therapeutics Achieves Research Milestone in Collaboration with Lilly

                            Details : Nimbus, in collaboration with Eli Lilly, has achieved a milestone by targeting a specific isoform of AMP-activated protein kinase (AMPK) for the treatment of cardiometabolic diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 25, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Eli Lilly

                            Deal Size : $496.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NDI-101150

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nimbus Therapeutics Announces Expansion of Its Immunology Drug Discovery Pipeline

                            Details : NDI-101150, a small molecule inhibitor of hematopoietic progenitor kinase 1 (HPK1) which is under phase 1/2 clinical development for the treatment of solid tumors.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 01, 2024

                            Lead Product(s) : NDI-101150

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Recipient : Anagenex

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Anagenex and Nimbus Announce a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Multiple...

                            Details : Under the collaboration, Anagenex and Nimbus will discover small molecule drugs for multiple challenging targets by applying Anagenex’s AI driven parallel biochemistry platform to generate experimentally measured datapoints for each of Nimbus’ nomina...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 18, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Recipient : Anagenex

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NDI-034858

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $6,000.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary

                            Details : Following the completion of this transaction, Takeda has now acquired TAK-279, formerly known at Nimbus as NDI-034858. This acquisition strengthens Takeda’s growing late-stage pipeline and potentially expands its portfolio and patient impact across mul...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $4,000.0 million

                            August 02, 2023

                            Lead Product(s) : NDI-034858

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $6,000.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NDI-101150

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Google Ventures

                            Deal Size : $210.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medici...

                            Details : Nimbus will use financing to continue the ongoing clinical development of NDI-101150, a hematopoietic progenitor kinase 1 (HPK1) inhibitor, in patients with solid tumors.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 09, 2023

                            Lead Product(s) : NDI-101150

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Google Ventures

                            Deal Size : $210.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NDI-034858

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $6,000.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Takeda to Acquire Nimbus Therapeutics’ Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immun...

                            Details : The acquisition strengthens Takeda's autoimmune portfolio, preferably NDI-034858 candidate, an oral, selective allosteric TYK2 inhibitor being evaluated for the treatment of multiple autoimmune diseases, especilally moderate to severe plaque psoriasis.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $4,000.0 million

                            December 13, 2022

                            Lead Product(s) : NDI-034858

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $6,000.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NDI-034858

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nimbus Therapeutics Announces Positive Topline Results for Phase 2b Clinical Trial of Allosteric TYK2 Inhibito...

                            Details : NDI-034858 is an allosteric TYK2 inhibitor developed by Nimbus Therapeutics that is being evaluated for the treatment of multiple autoimmune diseases. In preclinical studies, NDI-034858 has demonstrated exceptional functional selectivity and wide therape...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 30, 2022

                            Lead Product(s) : NDI-034858

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Discovery

                            Sponsor : Eli Lilly

                            Deal Size : $496.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Small Molecule Activ...

                            Details : Nimbus’s computational drug discovery engine and expertise in structure-based drug design, Nimbus is uniquely positioned to develop isoform-selective small molecule activators of AMPK with potential therapeutic application to a broad range of metabolic...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 10, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Discovery

                            Sponsor : Eli Lilly

                            Deal Size : $496.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Nimbus Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NDI-034858

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nimbus Therapeutics Presents New Data on Oral Allosteric TYK2 Inhibitor at American Chemical Society Meeting

                            Details : In a Phase 1 clinical study, NDI-034858 demonstrated a good tolerability profile and evidence of clinical and pharmacodynamic activity across multiple measures of disease pathology in psoriasis.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 24, 2022

                            Lead Product(s) : NDI-034858

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth